Gateway Investment Advisers LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 17.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,295 shares of the company's stock after acquiring an additional 1,851 shares during the period. Gateway Investment Advisers LLC's holdings in IDEXX Laboratories were worth $8,318,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the business. Ponta Wealth Partners LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $225,000. Navellier & Associates Inc. purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $5,274,000. Swedbank AB raised its holdings in shares of IDEXX Laboratories by 0.3% during the 4th quarter. Swedbank AB now owns 37,962 shares of the company's stock valued at $25,682,000 after buying an additional 130 shares in the last quarter. QRG Capital Management Inc. raised its holdings in shares of IDEXX Laboratories by 29.3% during the 4th quarter. QRG Capital Management Inc. now owns 2,496 shares of the company's stock valued at $1,688,000 after buying an additional 566 shares in the last quarter. Finally, Pinnacle Wealth Management Advisory Group LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $214,000. Hedge funds and other institutional investors own 87.84% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on IDXX. UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 28th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a research report on Tuesday, March 31st. BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research report on Tuesday, February 3rd. Finally, Piper Sandler cut their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research report on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $751.00.
View Our Latest Stock Analysis on IDXX
IDEXX Laboratories Trading Down 1.2%
NASDAQ IDXX opened at $572.20 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $485.40 and a twelve month high of $769.98. The firm has a market capitalization of $45.14 billion, a PE ratio of 42.14, a P/E/G ratio of 3.37 and a beta of 1.58. The stock's 50 day moving average is $585.67 and its 200 day moving average is $649.95.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the company posted $2.91 earnings per share. The company's revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 14.64 earnings per share for the current fiscal year.
Insider Transactions at IDEXX Laboratories
In other news, EVP Nimrata Hunt sold 2,693 shares of the business's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the transaction, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. The trade was a 11.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares of the company's stock, valued at $54,975,125.30. This represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 45,957 shares of company stock valued at $29,862,109. Insiders own 0.79% of the company's stock.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
